THE EFFECT OF INTERLEUKIN-6 AND SOLUBLE INTERLEUKIN-6 RECEPTOR PROTEIN ON THE BONE RESORPTIVE ACTIVITY OF HUMAN OSTEOCLASTS GENERATED IN-VITRO

被引：15

作者：

FLANAGAN, AM

STOW, MD

WILLIAMS, R

机构：

[1] UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT HISTOPATHOL,LONDON W2 1PG,ENGLAND

[2] ST MARYS HOSP,DEPT ORTHOPAED SURG,LONDON W2 1PG,ENGLAND

来源：

JOURNAL OF PATHOLOGY | 1995年 / 176卷 / 03期

关键词：

OSTEOCLAST; BONE RESORPTION; INTERLEUKIN-6; VITRONECTIN RECEPTOR; MACROPHAGES; PROSTAGLANDIN E(2); GIANT CELL TUMOR OF BONE;

D O I：

10.1002/path.1711760311

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The role of interleukin-6 (IL-6) in the regulation of bone resorption is controversial and has not been studied using human tissue in vitro. This study exploits a recently described in vitro model, whereby osteoclasts, defined as cells that resorb bone, can be generated from human bone marrow, and investigated the effect of IL-6 and its soluble receptor on bone resorption, in the presence of 1,25-dihydroxyvitamin D-3 [1,25(OH)(2) vitamin D-3]. Human bone marrow was cultured to form a confluent stroma, sedimented onto devitalized bone slices, and recharged with non-adherent bone marrow cells. 1,25(OH)(2) vitamin D-3 increased bone resorption, whereas IL-6 failed to induce a similar stimulatory effect. Both IL-6 at 100 ng/ml and soluble IL-6 receptor protein in the absence of exogenous IL-6 inhibited the stimulatory effect of 1,25(OH)(2) vitamin D-3. Bone resorption was never observed when non-adherent haemopoietic cells were cultured in the absence of stroma but in the presence of IL-6, which indicates that IL-6 cannot replace the stromal factor(s) required for the formation of cells capable of resorbing bone. These results suggest that IL-6 at high concentrations is not a critical cytokine in stimulating osteoclastic bone resorption.

引用

页码：289 / 297

页数：9

共 38 条

[21]

Davies J, Warwick J, Tutty N, Et al., The osteoclast functional antigen implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor, J Cell Biol, 109, pp. 1817-1826, (1989)

[22]

Chambers TJ, Fuller K, McSheehy PMJ, Pringle JAS, The effect of calcium‐regulating hormones on bone resorption by isolated osteoclastoma cells, J Pathol, 145, pp. 297-305, (1985)

[23]

Horton MA, Lewis D, McNulty K, Pringle JAS, Chambers TJ, Monoclonal antibodies to osteoclastomas (giant cell bone tumours): definition of osteoclast‐specific cellular antigens, Cancer Res, 45, pp. 5663-5669, (1985)

[24]

Nicholson GC, Horton MA, Sexteon PM, Et al., Calcitonin receptors of human osteoclastoma, Hormone Metab Res, 19, pp. 585-589, (1987)

[25]

Kaye M, When is it an osteoclast?, J Clin Pathol, 37, pp. 398-400, (1984)

[26]

Chambers TJ, Magnus CJ, Calcitonin alters behaviour of isolated osteoclasts, J Pathol, 136, pp. 27-39, (1982)

[27]

Warshawsky J, Goltzman D, Rouleau MF, Bergeron JJM, Direct in‐vivo demonstration by autoradiography of specific binding sites for calcitonin in skeletal and renal tissues of the rat, J Cell Biol, 85, pp. 682-694, (1980)

[28]

Nicholson GC, Livesey SA, Moseley JM, Martin TJ, Actions of calcitonin, parathyroid hormone and prostaglandin E<sub>2</sub> on cyclic AMP formation in chicken and rat osteoclasts, J Cell Biochem, 31, pp. 229-241, (1986)

[29]

Horton MA, Chambers TJ, Human osteoclast‐specific antigens are expressed by osteoclasts in a wide range of non‐human species, Br J Exp Pathol, 67, pp. 95-104, (1986)

[30]

Shabo Y, Lotem J, Rubinstein M, Et al., The myeloid blood cell differentiation‐inducing protein MG1–2A is interleukin‐6, Blood, 72, pp. 2070-2073, (1988)

← 1 2 3 4 →